<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Peeling skin syndromes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Peeling skin syndromes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Peeling skin syndromes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eli Sprecher, MD, PhD, MBA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Liat Samuelov, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H109776710"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Peeling skin syndromes (PSSs) are a heterogeneous group of rare, autosomal recessive disorders characterized by superficial, painless peeling and blistering of the skin without mucosal fragility [<a href="#rid1">1-3</a>]. The two major forms are acral peeling skin syndrome (APSS; also called localized PSS) and generalized PSS [<a href="#rid4">4-7</a>]. The latter is subclassified into noninflammatory (type A) and inflammatory (type B) PSS [<a href="#rid8">8,9</a>].</p><p>Although PSS was previously considered a subtype of epidermolysis bullosa simplex, it is now classified as a separate entity in the group of "other disorders with skin fragility."</p><p>This topic will review the pathogenesis, clinical features, and management of PSS. Congenital blistering diseases and keratinization disorders are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15452.html" rel="external">"Diagnosis of epidermolysis bullosa"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15453.html" rel="external">"Overview of the management of epidermolysis bullosa"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a>.)</p><p></p><p class="headingAnchor" id="H109776716"><span class="h1">ACRAL PEELING SKIN SYNDROME</span><span class="headingEndMark"> — </span>The localized form of peeling skin syndrome (PSS), called acral peeling skin syndrome (APSS) or PSS type 2 (MIM #609796), is a rare, autosomal recessive disorder caused by mutations in two genes: <em>TGM5</em>, encoding transglutaminase 5 (TGM5), implicated in the large majority of cases [<a href="#rid4">4,10</a>], and <em>CSTA</em> (PSS type 4, MIM #607936), encoding cystatin A, a cysteine protease inhibitor [<a href="#rid11">11,12</a>]. APSS manifests at birth or in early infancy and is characterized by skin exfoliation limited to the hands and feet.</p><p class="headingAnchor" id="H316952002"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>The precise incidence and prevalence of APSS are unknown due to being underreported, relatively mild, and easily misdiagnosed as other skin fragility disorders (eg, localized forms of epidermolysis bullosa simplex). The vast majority of reported patients are from European countries, suggesting a founder effect. Sporadic cases from Africa have been reported [<a href="#rid5">5,13,14</a>]. However, very few cases have been reported from outside Europe, perhaps reflecting geographical restriction of a common founder mutation. In European populations, the estimated carrier frequency of the most common <em>TGM5</em> mutation, p.Gly113Cys, is approximately 3 percent, predicting a disease prevalence of up to 1 in 4500 [<a href="#rid4">4,15</a>]. More than 160 patients with APSS have been reported, with <em>TGM5</em> mutations found in over 90 percent of cases [<a href="#rid6">6,10,16</a>].</p><p class="headingAnchor" id="H109776724"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>APSS is caused by biallelic (homozygous or compound heterozygous) mutations in the <em>TGM5</em> gene, encoding TGM5 [<a href="#rid4">4,10</a>]. Crucial for normal epidermal differentiation, transglutaminases are a family of enzymes involved in the cross-linking of cornified cell envelope proteins through the formation of gamma-glutamyl-lysine isodipeptide bonds between adjacent polypeptides [<a href="#rid15">15,17-19</a>]. Therefore, mutations in <em>TGM5</em> completely abolish cross-linking activity, leading to the detachment of the stratum corneum from the underlying stratum granulosum at the site of activity and expression of TGM5  (<a class="graphic graphic_figure graphicRef126488" href="/d/graphic/126488.html" rel="external">figure 1</a>) [<a href="#rid20">20</a>].</p><p><em>TGM5 </em>is located on 15q15.2, spans 33.7 kb of genomic deoxyribonucleic acid (DNA), and contains 13 exons. The TGM5 protein has three domains (beta-sandwich, beta-barrel 1, and beta-barrel 2) and an additional highly conserved, functionally important domain called the central catalytic core [<a href="#rid6">6,21</a>]. Most mutations affect amino acids located in the catalytic core and the beta-sandwich domains [<a href="#rid6">6</a>]. The most commonly reported mutation, p.Gly113Cys, is located within the beta-sandwich domain and has been found to abolish TGM5 activity [<a href="#rid4">4</a>].</p><p>There is no obvious phenotype-genotype correlation or variation in severity between homozygous and compound heterozygous patients. The phenotype can vary in severity both within and among families [<a href="#rid6">6</a>]. It has been shown that homozygous <em>ALOXE3</em> mutations resulting in a phenotype of autosomal recessive congenital ichthyosis rescue cell-cell adhesion defects due to homozygous <em>TGM5</em> mutations through corneodesmosin upregulation [<a href="#rid22">22</a>].</p><p>Homozygous mutations in the <em>CSTA</em> gene, encoding cystatin A, a member of a superfamily of protease inhibitors expressed in the cornified cell envelope, were reported in families with APSS without evidence of <em>TGM5 </em>mutations<em> </em>[<a href="#rid11">11,12,23</a>]. Other mutations in the same gene have been implicated in the pathogenesis of autosomal recessive exfoliative ichthyosis (AREI; MIM #607936), a rare type of congenital ichthyosis characterized by palmoplantar hyperkeratosis with extension to the dorsal aspects of hands and feet and acral skin peeling [<a href="#rid11">11,24-26</a>]. (See <a class="local">'Autosomal recessive exfoliative ichthyosis'</a> below.)</p><p>Of note, acral peeling of the skin has been reported as a minor feature of cutaneous serpinopathies due to loss-of-function defects in serpins, another class of protease inhibitors [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma", section on 'Palmoplantar keratoderma with SERPINA12 mutations'</a>.)</p><p class="headingAnchor" id="H52453532"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Histologically, APSS is characterized by compact orthokeratosis and detachment of the stratum corneum from the underlying stratum granulosum  (<a class="graphic graphic_picture graphicRef126682" href="/d/graphic/126682.html" rel="external">picture 1</a>) [<a href="#rid20">20</a>]. Electron microscopy, although not required for analysis, may reveal more subtle morphologic changes, including cleavage between cornified cells and disrupted tonofilament bundles.</p><p class="headingAnchor" id="H109776736"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Patients with APSS present with superficial peeling or blistering of the dorsal surfaces of hands and feet, palms, and soles, often associated with erythema  (<a class="graphic graphic_picture graphicRef126492 graphicRef126690" href="/d/graphic/126492.html" rel="external">picture 2A-B</a>) [<a href="#rid29">29,30</a>]. When present, blisters are superficial and flaccid, have a clear content, and rupture easily, resulting in exfoliation. Lesions occasionally involve the limbs and may be associated with mild pruritus [<a href="#rid11">11,24,31</a>].</p><p>Onset of symptoms is shortly after birth or in early childhood. Healing usually occurs spontaneously, sometimes with residual erythema, burning sensation, or pruritus, but without scarring or atrophy. Some patients present with only mild disease characterized by superficial peeling of dorsal and plantar areas of the hands and feet; however, episodes of aggravation may follow exposure to heat, mechanical trauma (friction), humidity, and exposure to water [<a href="#rid29">29</a>].</p><p>In most cases, skin peeling persists over time, whereas blistering tends to cease with age [<a href="#rid31">31</a>]. There are no known systemic manifestations nor abnormal laboratory findings.</p><p class="headingAnchor" id="H109776748"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of APSS is suspected in children or adults presenting with acral skin blistering and peeling in the absence of mucosal involvement and systemic manifestations. The definitive diagnosis is based upon  (<a class="graphic graphic_algorithm graphicRef100421" href="/d/graphic/100421.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Histopathologic analysis of a skin biopsy obtained from an area of skin peeling revealing separation between the stratum corneum and stratum granulosum. Electron microscopy analysis, although not required for diagnosis, may reveal more subtle morphologic changes, including cleavage between cornified cells with disrupted tonofilament bundles. (See <a class="local">'Pathology'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identification of causative variants in <em>TGM5</em> (or <em>CSTA</em>) by mutation analysis on DNA isolated from peripheral blood or other appropriate tissue.</p><p></p><p class="headingAnchor" id="H109776754"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of APSS includes several inherited and acquired conditions  (<a class="graphic graphic_algorithm graphicRef126688" href="/d/graphic/126688.html" rel="external">algorithm 2</a>). Among these, APSS is most frequently confused with localized epidermolysis bullosa simplex.</p><p class="headingAnchor" id="H316952205"><span class="h3">Epidermolysis bullosa simplex</span><span class="headingEndMark"> — </span>Localized epidermolysis bullosa simplex is an autosomal dominant disorder most often caused by mutations in the genes <em>KRT5</em> or <em>KRT14</em>, although numerous additional genes have been implicated [<a href="#rid32">32</a>]. Epidermolysis bullosa simplex is characterized by blisters and erosions on the palms and soles following mechanical trauma  (<a class="graphic graphic_picture graphicRef86390 graphicRef86391" href="/d/graphic/86390.html" rel="external">picture 3A-B</a>).</p><p>Ultrastructurally, epidermolysis bullosa simplex blisters are located in the basal layer of the epidermis and not in the upper epidermis, as in APSS [<a href="#rid33">33,34</a>]. Histopathologic and ultrastructural analysis of a skin biopsy and mutation analysis can clarify the diagnosis [<a href="#rid29">29,32</a>]. (See  <a class="medical medical_review" href="/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Epidermolysis bullosa simplex'</a>.)</p><p class="headingAnchor" id="H316952219"><span class="h3">Erythrokeratolysis hiemalis (keratolytic winter erythema)</span><span class="headingEndMark"> — </span>Erythrokeratolysis hiemalis is<strong> </strong>an autosomal dominant disorder characterized by recurrent episodes of palmoplantar erythema and epidermal peeling that exacerbate during the winter. A less common finding is a slowly migratory, annular erythema involving the extremities. Itching, hyperkeratosis, and hyperhidrosis are associated features. In contrast to APSS, keratolytic winter erythema features a more pronounced erythema and hyperkeratosis with normal-appearing skin between flares. The disease is caused by genomic changes affecting a regulatory region modulating the expression of the <em>CTSB</em> gene on chromosome 8p22-p23, encoding cathepsin B, a cysteine protease involved in keratinocyte differentiation and desquamation [<a href="#rid35">35-37</a>].</p><p class="headingAnchor" id="H109776770"><span class="h3">Keratolysis exfoliativa</span><span class="headingEndMark"> — </span>Keratolysis exfoliativa<strong> </strong>(also known as "dyshidrosis lamellosa sicca") is a palmoplantar dermatosis characterized by annular erythema over the volar aspects of the hands and feet with air-filled blisters heralding lamellar peeling  (<a class="graphic graphic_picture graphicRef126509 graphicRef126510" href="/d/graphic/126509.html" rel="external">picture 4A-B</a>). In contrast to APSS, it is characterized mainly by small, annular collarettes of white scale involving only the palms (and, less commonly, the soles) with no involvement of the dorsal aspects of hands and feet. In addition, no fluid-filled blisters are seen in this condition. Keratolysis exfoliativa<strong> </strong>worsens under warm weather and may be associated with hyperhidrosis. Friction and water contact may aggravate findings. This may be explained by damage to the stratum corneum in volar skin by mechanical forces or soaking. Histopathologic findings include cleavage within the stratum corneum, without an inflammatory infiltrate [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H109776812"><span class="h2">Management of acral peeling skin syndrome</span><span class="headingEndMark"> — </span>There is no specific therapy for APSS. Patients should be educated about avoidance of exacerbating factors, such as heat, friction, humidity, mechanical trauma, and excessive perspiration. Daily topical application of emollients to affected areas may be beneficial.</p><p class="headingAnchor" id="H316952558"><span class="h2">Genetic counseling</span><span class="headingEndMark"> — </span>All patients and their family members should be referred for genetic counseling. In patients of European ancestry suspected to have epidermolysis bullosa simplex but lacking mutations in the keratin genes, screening for the recurrent <em>TGM5</em> mutation p.Gly113Cys is indicated. If not found, direct sequencing of all coding regions of the <em>TGM5</em> gene is indicated.</p><p class="headingAnchor" id="H109776818"><span class="h1">GENERALIZED NONINFLAMMATORY (TYPE A) PEELING SKIN SYNDROME</span><span class="headingEndMark"> — </span>Generalized noninflammatory peeling skin syndrome (PSS), also called type A PSS (MIM #270300), is a rare, autosomal recessive disorder characterized by generalized, painless peeling of the skin that starts at birth or in early infancy. This type of PSS encompasses three major groups: PSS type 3 (MIM #616265), characterized by asymptomatic, superficial, generalized peeling [<a href="#rid8">8,39</a>]; PSS type 5 (MIM #617115), manifesting with skin peeling over the hands, feet, and knees associated with palmoplantar keratoderma [<a href="#rid40">40</a>]; and PSS type 6 (MIM #618084), characterized by generalized, dry skin and peeling lesions on the trunk and limbs at sites of minor trauma [<a href="#rid41">41-43</a>].</p><p class="headingAnchor" id="H109776826"><span class="h2">Pathogenesis</span></p><p class="headingAnchor" id="H1209683770"><span class="h3">Peeling skin syndrome type 3</span><span class="headingEndMark"> — </span>In a large consanguineous Pakistani family, type A PSS (generalized noninflammatory PSS) was associated with a homozygous <em>CHST8</em> mutation, c.229C&gt;T, within exon 4, using a combination of autozygosity mapping and whole exome sequencing [<a href="#rid8">8</a>]. <em>CHST8</em> encodes a carbohydrate sulfotransferase, N-acetylgalactosamine-4-O-sulfotransferase 1 (GalNAc4-ST1), which is a type II transmembrane protein that functions almost exclusively in the Golgi apparatus and transfers sulfate groups to the C4 hydroxyl group of terminal beta-1,4-linked N-acetylgalactosamine [<a href="#rid44">44</a>]. GalNAc4-ST1 is highly expressed in the pituitary gland, cerebellum, and brain, where it is required for the biosynthesis of the glycoprotein hormones LH and thyrotropin [<a href="#rid44">44</a>]. </p><p>However, the association of type A PSS with <em>CHST8</em> has been questioned. A subsequent study indicated that <em>CHST8</em> is weakly expressed in keratinocytes and that the mutant protein found in association with PSS type 3 in one family resulted in a normal activity [<a href="#rid39">39</a>]. Moreover, the PSS type 3-associated <em>CHST8</em> variant is frequently found in the general population, which does not fit the rarity of the PSS phenotype, suggesting that it represents a neutral nonpathogenic polymorphism [<a href="#rid39">39</a>]. </p><p class="headingAnchor" id="H1211927207"><span class="h3">Peeling skin syndrome type 5</span><span class="headingEndMark"> — </span>Homozygous loss-of-function mutations in the gene <em>SERPINB8</em>, encoding serpin peptidase inhibitor, clade B, member 8, result in noninflammatory peeling of the skin, also referred to as "exfoliative ichthyosis." SERPINB8 protein absence in patients' skin results in impaired cell-cell adhesion, especially following exposure to mechanical stress [<a href="#rid40">40</a>]. Of note, homozygous mutation in another member of the same family of peptidase inhibitors, <em>SERPINB7</em>, has been shown to result in the acral peeling phenotype in patients with palmoplantar keratosis Nagashima type through reduced desmoglein 1 and desmocollin 1 expression, which results in desquamation and impaired keratinocyte adhesion [<a href="#rid27">27</a>]. </p><p class="headingAnchor" id="H294177285"><span class="h3">Peeling skin syndrome type 6</span><span class="headingEndMark"> — </span>Biallelic loss-of-function mutations in <em>FLG2</em>, encoding filaggrin 2, have been reported in three consanguineous families of Saudi, Moroccan, and Israeli origins with generalized noninflammatory PSS [<a href="#rid41">41-43</a>]. Reduced filaggrin expression at the RNA and protein level in patients' epidermis resulted in impaired cell-cell adhesion through reduction in corneodesmosin expression, which is a crucial component of corneodesmosomes, intercellular junctions located in the uppermost layers of the epidermis. This effect is enhanced by temperature elevation, consistent with the observed clinical exacerbation of PSS type 6 by warm weather [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H316952681"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Type A PSS is characterized by slight hyperkeratosis, thinning of the granular layer, and separation of the stratum corneum from the underlying stratum granulosum or intracorneal split [<a href="#rid8">8,41-43,45</a>]. Electron microscopy shows intracellular cytoplasmic splitting in the lower stratum corneum and abnormal cribriform or reduced keratohyalin granules, which are indicative of disturbed keratinization [<a href="#rid41">41-43</a>]. In some patients, reduced desmosomal plaques or intracellular electron-dense globular deposits within the stratum corneum have also been observed [<a href="#rid46">46-48</a>].</p><p>PSS type 5 is characterized by cell-cell disadhesion within the Malpighian layer of the epidermis [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H3992737449"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Type A PSS presents at birth or in early childhood with generalized, white to skin-colored scaling, most prominent over the upper and lower extremities, including areas of large joints [<a href="#rid40">40</a>], with painless and easy removal of the stratum corneum of the skin  (<a class="graphic graphic_picture graphicRef126689" href="/d/graphic/126689.html" rel="external">picture 5</a>) [<a href="#rid49">49,50</a>]. Exacerbations may occur following contact with water, dust, and sand. In addition, sliding friction forces may induce peeling [<a href="#rid49">49</a>]. Thickened skin with diffuse, yellowish, hyperkeratotic plaques over the palms and soles may be seen in PSS type 5 [<a href="#rid40">40,41</a>]. Hyperkeratosis over the knees and elbows is also typical of PSS type 5 [<a href="#rid42">42</a>]. PSS type 6 is characterized by superficial peeling of the skin over the trunk and extremities at sites exposed to trauma, with residual hyperpigmentation following healing.</p><p>Erythema; pruritus; atopic manifestations; hair, nail, and mucous abnormalities; and systemic involvement are usually absent [<a href="#rid8">8</a>]. Routine laboratory tests, including immunoglobulin E (IgE) serum levels, are normal. There is a case report of type A PSS associated with aminoaciduria, with increased urine excretion of cystine and histidine [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H109776844"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of type A PSS is often delayed due to late presentation in less severe and asymptomatic cases. Similar to acral peeling skin syndrome, the diagnosis of type A PSS is suspected in a patient presenting with painless skin peeling since birth or early childhood. A skin biopsy from involved areas of skin peeling is necessary for the diagnosis (see <a class="local">'Pathology'</a> above). Ultrastructural analysis using electron microscopy, if available, may provide additional information, although this is not necessary for the diagnosis. </p><p>Molecular analysis for mutations in <em>SERPINB8 </em>or <em>FLG2 </em>is indicated in patients and family members for definitive diagnosis  (<a class="graphic graphic_algorithm graphicRef100421" href="/d/graphic/100421.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H109776850"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of generalized noninflammatory PSS includes a number of genodermatoses characterized by scaly skin in the absence of erythema  (<a class="graphic graphic_algorithm graphicRef126688" href="/d/graphic/126688.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H109776869"><span class="h3">Superficial epidermolytic ichthyosis</span><span class="headingEndMark"> — </span>Superficial epidermolytic ichthyosis (formerly called "ichthyosis bullosa of Siemens"; MIM #146800) is a rare, autosomal dominant genodermatosis caused by heterozygous mutations in the gene <em>KRT2</em>, encoding keratin 2. The disease is characterized by mild blistering in early infancy that usually subsides by early childhood when hyperkeratosis develops. An additional characteristic feature is superficial peeling described as "Mauserung (moulting) phenomenon," secondary to superficial blistering and shedding of the stratum corneum [<a href="#rid52">52</a>]. No systemic manifestations or abnormal laboratory findings are evident. Histopathologic findings are characteristic epidermolytic changes. (See  <a class="medical medical_review" href="/d/html/97333.html" rel="external">"Keratinopathic ichthyoses", section on 'Superficial epidermolytic ichthyosis'</a>.) </p><p class="headingAnchor" id="H2437320134"><span class="h3">PLACK syndrome</span><span class="headingEndMark"> — </span><strong>P</strong>eeling skin, <strong>l</strong>eukonychia, <strong>a</strong>cral punctate keratoses, <strong>c</strong>heilitis, and <strong>k</strong>nuckle pads (PLACK; MIM #616295) syndrome is a form of peeling skin caused by loss-of-function variants in the <em>CAST </em>gene, encoding calpastatin, which is an inhibitor of the calcium-dependent cysteine protease calpain [<a href="#rid53">53-58</a>]. These variants result in reduced calpastatin expression and activity, resulting in defective adhesion and increased epidermal desquamation. PLACK syndrome has been shown to be associated with low levels of vitamin A and essential fatty acids. In a single case report, treatment with intravenous infusions of lipid emulsions containing fat-soluble vitamins resulted in remarkable improvement in pruritus and skin lesions [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H1648937124"><span class="h3">Autosomal recessive exfoliative ichthyosis</span><span class="headingEndMark"> — </span>Autosomal recessive exfoliative ichthyosis (AREI; PSS type 4; MIM #607936) is an autosomal recessive disease caused by loss-of-function mutations in <em>CSTA</em>, encoding cystatin A (see <a class="local">'Acral peeling skin syndrome'</a> above). AREI is characterized by circumscribed, nonerythematous peeling of the skin on the hands, feet, and neck and by generalized, white scaling. Histopathology shows abnormal cell-cell adhesion in the lower epidermal layers [<a href="#rid25">25,26</a>]. Ultrastructurally, AREI is characterized by impaired desmosome morphology in the lower epidermal layers, reduced thickness of the cornified envelope, disturbed lamellar lipid bilayer, premature lamellar body secretion, and delayed processing of secreted lamellar body contents [<a href="#rid25">25,26</a>]. In contrast to PSS, the level of detachment by electron microscopy is in the basal and lower suprabasal layers of the epidermis [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H109776875"><span class="h2">Management of generalized noninflammatory peeling skin syndrome</span><span class="headingEndMark"> — </span>There is no specific therapy for type A PSS. Patients should be educated about avoiding exacerbating factors, such as heat, friction, humidity, mechanical trauma, and excessive perspiration. Daily topical application of emollients to affected areas may be beneficial.</p><p>Systemic retinoids, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, topical and systemic corticosteroids, tar, and ultraviolet B (UVB) phototherapy have been used without success in a few patients [<a href="#rid1">1,47,49,60-62</a>]. Some improvement with topical <a class="drug drug_general" data-topicid="9181" href="/d/drug information/9181.html" rel="external">calcipotriol</a> has been documented in a single patient [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H109776881"><span class="h1">GENERALIZED INFLAMMATORY (TYPE B) PEELING SKIN SYNDROME</span><span class="headingEndMark"> — </span>Generalized inflammatory peeling skin syndrome (PSS), also called type B PSS (PSS type 1; MIM #270300), is a rare, autosomal recessive genodermatosis that results from loss-of-function mutations in the <em>CDSN</em> gene, encoding corneodesmosin [<a href="#rid9">9</a>]. Type B PSS presents at birth or in early childhood with widespread peeling of the skin associated with erythroderma, severe pruritus, and atopic manifestations.</p><p class="headingAnchor" id="H109776889"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Type B PSS (generalized inflammatory PSS) is caused by loss-of-function mutations in <em>CDSN</em>, encoding corneodesmosin, with complete loss of protein expression in the epidermis [<a href="#rid9">9,64-67</a>]. Genomic deletion at the <em>PSORS1</em> locus removing the entire <em>CDSN </em>gene and a large, homozygous deletion of six genes, including <em>CDSN</em>,<em> </em>have also been<em> </em>reported as the cause of type B PSS [<a href="#rid68">68,69</a>]. This genomic deletion resulting from a founder mutation has been identified in several Japanese patients with PSS [<a href="#rid70">70</a>].</p><p>Corneodesmosin is an extracellular 52 to 56 kDa glycoprotein that contributes to the formation of corneodesmosomes, critical intercellular junctions in the upper epidermal layers. This protein plays a role in reinforcing cell-cell adhesion in the upper epidermis, and its degradation by epidermal proteases is essential for normal desquamation [<a href="#rid71">71,72</a>]. The absence of corneodesmosin in patients with type B PSS results in impaired cell-cell coherence in the upper epidermis [<a href="#rid73">73</a>]. The defective skin barrier function leads to increased permeability to allergens and microbes, predisposing to atopic manifestations and skin infections [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H316952963"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>On histology, type B PSS shows subcorneal separation with mild, inflammatory infiltrate in the upper dermis. Electron microscopy shows evidence of split formation between the keratinocytes of the stratum granulosum and corneocytes of the stratum corneum and loss of corneodesmosomes [<a href="#rid9">9</a>]. Total absence of corneodesmosin expression in the epidermis, demonstrated by immunohistochemistry, can confirm the diagnosis.</p><p class="headingAnchor" id="H109776895"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Type B PSS presents at birth or during early infancy with spontaneous and widespread peeling of the skin associated with erythroderma that persists into adulthood  (<a class="graphic graphic_picture graphicRef126691" href="/d/graphic/126691.html" rel="external">picture 6</a>). Additional major features are severe pruritus, food allergies, asthma, repeated episodes of angioedema, and urticaria. Patients may exhibit failure to thrive and recurrent skin infections, especially with <em>Staphylococcus aureus </em>[<a href="#rid9">9,64,66</a>]. The condition is usually not associated with any hair abnormalities. However, a single case associated with trichorrhexis invaginata has been reported [<a href="#rid74">74</a>]. </p><p>Characteristic laboratory findings are elevated IgE levels and eosinophilia. </p><p class="headingAnchor" id="H109776907"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of type B PSS is based upon the combination of clinical and laboratory findings  (<a class="graphic graphic_algorithm graphicRef100421" href="/d/graphic/100421.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Widespread skin peeling associated with erythroderma, severe pruritus, and atopic manifestations, including food allergies and asthma</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated levels of serum IgE and eosinophilia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histopathologic findings of subcorneal separation with mild, inflammatory infiltrate in the upper dermis and absent corneodesmosin stain on immunohistochemistry</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of loss of corneodesmosomes on electron microscopy</p><p></p><p class="headingAnchor" id="H109776913"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of type B PSS includes several acquired and inherited disorders. Due to considerable phenotypic overlap, the differentiation of type B PSS from Netherton syndrome and <strong>s</strong>evere dermatitis, multiple <strong>a</strong>llergies, and <strong>m</strong>etabolic wasting (SAM) syndrome requires mutational analysis  (<a class="graphic graphic_algorithm graphicRef126688" href="/d/graphic/126688.html" rel="external">algorithm 2</a>) [<a href="#rid46">46,73</a>].</p><p class="headingAnchor" id="H316953004"><span class="h3">Netherton syndrome</span><span class="headingEndMark"> — </span>Netherton syndrome (MIM #256500) is an autosomal recessive genodermatosis caused by loss-of-function mutations in the serine protease inhibitor of Kazal type 5 <em>(SPINK5</em>) gene, encoding the serine protease inhibitor lympho-epithelial Kazal type related inhibitor type 5 (LEKTI) [<a href="#rid75">75-77</a>]. Netherton syndrome is characterized by congenital erythroderma, occasionally complicated with hypernatremic dehydration and sepsis, which usually evolves into a widespread eruption consisting of serpiginous plaques with typical double-edged scales (known as "ichthyosis linearis circumflexa"  (<a class="graphic graphic_picture graphicRef87482" href="/d/graphic/87482.html" rel="external">picture 7</a>)) [<a href="#rid78">78-85</a>]. Eosinophilia and elevated IgE levels are common laboratory findings [<a href="#rid86">86</a>]. Additional clinical findings include eczematous, atopic dermatitis-like lesions; characteristic hair abnormalities (trichorrhexis invaginata  (<a class="graphic graphic_picture graphicRef87481" href="/d/graphic/87481.html" rel="external">picture 8</a>)); failure to thrive; atopic manifestations (eg, asthma, allergic rhinitis, food allergies); urticaria; angioedema; and often severe reactions [<a href="#rid87">87-92</a>]. (See  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses", section on 'Netherton syndrome'</a>.)</p><p class="headingAnchor" id="H316953017"><span class="h3">SAM syndrome</span><span class="headingEndMark"> — </span><strong>S</strong>evere dermatitis, multiple <strong>a</strong>llergies, and <strong>m</strong>etabolic wasting (SAM) syndrome (MIM #615508) is a genodermatosis first described in 2013 caused by homozygous mutations in <em>DSG1</em>, encoding desmoglein 1, a cadherin-like transmembrane glycoprotein that is an essential component of the desmosomes in the upper epidermal layers [<a href="#rid93">93-98</a>]. Isolated cases of SAM syndrome caused by a point mutation in the <em>DSP</em> gene, encoding desmoplakin, have been described [<a href="#rid99">99-101</a>]. Desmoplakin is an obligate component of functional desmosomes that anchors intermediate filaments to desmosomal plaques.</p><p>SAM syndrome is characterized by congenital erythroderma, striate palmoplantar keratoderma (yellowish papules and plaques at the periphery of the palms, along the fingers, and over weight-bearing areas of the feet), skin erosions, scaling, and hypotrichosis. Additional features are severe food allergies, recurrent skin and respiratory infections, eosinophilic esophagitis, esophageal reflux, minor cardiac defects, failure to thrive, and growth retardation. Elevated IgE level is a common laboratory finding [<a href="#rid73">73,93-98,102-104</a>]. Cases resulting from <em>DSP</em> mutations are also associated with pustular lesions [<a href="#rid99">99-101</a>].</p><p class="headingAnchor" id="H109776934"><span class="h2">Management of generalized inflammatory peeling skin syndrome</span><span class="headingEndMark"> — </span>There is no specific therapy for type B PSS. Patients should be educated about avoidance of exacerbating factors, such as heat, friction, humidity, mechanical trauma, and excessive perspiration. Daily topical application of emollients to affected areas may be beneficial.</p><p>In a single case report, treatment with <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> reduced IgE levels but did not improve the skin manifestations or quality of life [<a href="#rid105">105</a>]. A role for antihistamines and kallikrein inhibitors in the treatment of type B PSS has been hypothesized based upon the observation in vitro that histamine attenuates the expression of desmosomal proteins, including <em>CDSN</em>, in human keratinocytes, and kallikreins are upregulated in type B PSS [<a href="#rid106">106-112</a>]. However, due to the rarity of type B PSS, clinical experience with these agents is lacking.</p><p>A preclinical study with liposomal encapsulated recombinant human <em>CDSN</em> demonstrated promising results in primary keratinocytes and human epidermal equivalents [<a href="#rid113">113</a>]. </p><p class="headingAnchor" id="H316953238"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and classification</strong> – Peeling skin syndromes (PSSs) are a heterogeneous group of rare, autosomal recessive disorders characterized by superficial, painless peeling and blistering of the skin without mucosal fragility. The two major forms of PSS are localized/acral peeling skin syndrome (APSS) and generalized PSS. The latter is subclassified into noninflammatory (type A) and inflammatory (type B) PSS. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acral peeling skin syndrome</strong> – APSS is in most cases caused by mutations in the <em>TGM5</em> gene, encoding transglutaminase 5, involved in the cross-linking of cornified cell envelope proteins. APSS manifests at birth or in early infancy and is characterized by skin exfoliation limited to the hands and feet. Rare cases may result from mutations in <em>CSTA</em>, encoding cystatin A, a cysteine protease inhibitor. (See <a class="local">'Acral peeling skin syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Generalized noninflammatory peeling skin syndrome</strong> – Generalized noninflammatory PSS, or type A PSS, may result from homozygous mutations in the genes<em> SERPINB8</em> or <em>FLG2</em>, encoding serpin peptidase inhibitor, clade B, member 8, and filaggrin 2, respectively. Type A PSS presents at birth or early childhood in most cases with generalized, white to skin-colored scaling that is most prominent over the upper and lower extremities, with painless and easy removal of the skin. (See <a class="local">'Generalized noninflammatory (type A) peeling skin syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Generalized inflammatory peeling skin syndrome</strong> – Generalized inflammatory PSS, or type B PSS, is caused by loss-of-function mutations in the <em>CDSN</em> gene, encoding corneodesmosin. Type B PSS presents at birth or in early childhood with widespread peeling of the skin associated with erythroderma, severe pruritus, and atopic manifestations. (See <a class="local">'Generalized inflammatory (type B) peeling skin syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis and differential diagnosis of PSS are based on the combination of clinical features, routine laboratory tests, histopathologic and ultrastructural analysis of a skin biopsy, and mutation analysis  (<a class="graphic graphic_algorithm graphicRef100421" href="/d/graphic/100421.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef126688" href="/d/graphic/126688.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – There are no specific therapies for PSS. Improvement of scaling and blistering may be observed with avoidance of exacerbating factors, such as heat, friction, humidity, mechanical trauma (eg, using padding or appropriate footwear), and excessive perspiration, as well as daily topical application of emollients to affected areas. (See <a class="local">'Management of acral peeling skin syndrome'</a> above and <a class="local">'Management of generalized noninflammatory peeling skin syndrome'</a> above and <a class="local">'Management of generalized inflammatory peeling skin syndrome'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Levy SB, Goldsmith LA. The peeling skin syndrome. J Am Acad Dermatol 1982; 7:606.</a></li><li><a class="nounderline abstract_t">Hacham-Zadeh S, Holubar K. Skin peeling syndrome in a Kurdish family. Arch Dermatol 1985; 121:545.</a></li><li><a class="nounderline abstract_t">Has C. Peeling Skin Disorders: A Paradigm for Skin Desquamation. J Invest Dermatol 2018; 138:1689.</a></li><li><a class="nounderline abstract_t">Cassidy AJ, van Steensel MA, Steijlen PM, et al. A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome. Am J Hum Genet 2005; 77:909.</a></li><li><a class="nounderline abstract_t">Kharfi M, El Fekih N, Ammar D, et al. A missense mutation in TGM5 causes acral peeling skin syndrome in a Tunisian family. J Invest Dermatol 2009; 129:2512.</a></li><li><a class="nounderline abstract_t">Szczecinska W, Nesteruk D, Wertheim-Tysarowska K, et al. Under-recognition of acral peeling skin syndrome: 59 new cases with 15 novel mutations. Br J Dermatol 2014; 171:1206.</a></li><li><a class="nounderline abstract_t">Shwayder T, Conn S, Lowe L. Acral peeling skin syndrome. Arch Dermatol 1997; 133:535.</a></li><li><a class="nounderline abstract_t">Cabral RM, Kurban M, Wajid M, et al. Whole-exome sequencing in a single proband reveals a mutation in the CHST8 gene in autosomal recessive peeling skin syndrome. Genomics 2012; 99:202.</a></li><li><a class="nounderline abstract_t">Oji V, Eckl KM, Aufenvenne K, et al. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. Am J Hum Genet 2010; 87:274.</a></li><li><a class="nounderline abstract_t">van der Velden JJ, van Geel M, Nellen RG, et al. Novel TGM5 mutations in acral peeling skin syndrome. Exp Dermatol 2015; 24:285.</a></li><li><a class="nounderline abstract_t">Krunic AL, Stone KL, Simpson MA, McGrath JA. Acral peeling skin syndrome resulting from a homozygous nonsense mutation in the CSTA gene encoding cystatin A. Pediatr Dermatol 2013; 30:e87.</a></li><li><a class="nounderline abstract_t">Muttardi K, Nitoiu D, Kelsell DP, et al. Acral peeling skin syndrome associated with a novel CSTA gene mutation. Clin Exp Dermatol 2016; 41:394.</a></li><li><a class="nounderline abstract_t">Kiprono SK, Chaula BM, Naafs B, Masenga JE. Acral peeling skin syndrome in two East-African siblings: case report. BMC Dermatol 2012; 12:2.</a></li><li><a class="nounderline abstract_t">Mathew R, Omole OB, Rigby J, Grayson W. Adult-onset acral peeling skin syndrome in a non-identical twin: a case report in South Africa. Am J Case Rep 2014; 15:589.</a></li><li><a class="nounderline abstract_t">Pigors M, Kiritsi D, Cobzaru C, et al. TGM5 mutations impact epidermal differentiation in acral peeling skin syndrome. J Invest Dermatol 2012; 132:2422.</a></li><li><a class="nounderline abstract_t">Cañueto J, Bueno E, Rodríguez-Diaz E, et al. Acral peeling skin syndrome resulting from mutations in TGM5. J Eur Acad Dermatol Venereol 2016; 30:477.</a></li><li><a class="nounderline abstract_t">Kalinin AE, Kajava AV, Steinert PM. Epithelial barrier function: assembly and structural features of the cornified cell envelope. Bioessays 2002; 24:789.</a></li><li><a class="nounderline abstract_t">Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005; 6:328.</a></li><li><a class="nounderline abstract_t">Lorand L, Iismaa SE. Transglutaminase diseases: from biochemistry to the bedside. FASEB J 2019; 33:3.</a></li><li><a class="nounderline abstract_t">García EG, Carreño RG, Martínez González MA, Reyes JJ. Acral peeling skin syndrome: report of two cases. Ultrastruct Pathol 2005; 29:65.</a></li><li><a class="nounderline abstract_t">Grenard P, Bates MK, Aeschlimann D. Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem 2001; 276:33066.</a></li><li><a class="nounderline abstract_t">Mohamad J, Nanda A, Pavlovsky M, et al. Phenotypic suppression of acral peeling skin syndrome in a patient with autosomal recessive congenital ichthyosis. Exp Dermatol 2020; 29:742.</a></li><li><a class="nounderline abstract_t">Sarika GM, Ibrahim R, Zlotogorski A, Molho-Pessach V. Acral peeling skin syndrome resulting from a novel homozygous mutation in the CSTA gene-A report of two cases. Pediatr Dermatol 2021; 38:1546.</a></li><li><a class="nounderline abstract_t">Pavlovic S, Krunic AL, Bulj TK, et al. Acral peeling skin syndrome: a clinically and genetically heterogeneous disorder. Pediatr Dermatol 2012; 29:258.</a></li><li><a class="nounderline abstract_t">Blaydon DC, Nitoiu D, Eckl KM, et al. Mutations in CSTA, encoding Cystatin A, underlie exfoliative ichthyosis and reveal a role for this protease inhibitor in cell-cell adhesion. Am J Hum Genet 2011; 89:564.</a></li><li><a class="nounderline abstract_t">Moosbrugger-Martinz V, Jalili A, Schossig AS, et al. Epidermal barrier abnormalities in exfoliative ichthyosis with a novel homozygous loss-of-function mutation in CSTA. Br J Dermatol 2015; 172:1628.</a></li><li><a class="nounderline abstract_t">Cohen-Barak E, Azzam W, Koetsier JL, et al. Acral peeling in Nagashima type palmo-plantar keratosis patients reveals the role of serine protease inhibitor B 7 in keratinocyte adhesion. Exp Dermatol 2022; 31:214.</a></li><li><a class="nounderline abstract_t">Mohamad J, Sarig O, Malki L, et al. Loss-of-Function Variants in SERPINA12 Underlie Autosomal Recessive Palmoplantar Keratoderma. J Invest Dermatol 2020; 140:2178.</a></li><li><a class="nounderline abstract_t">Kavaklieva S, Yordanova I, Bruckner-Tuderman L, Has C. Acral peeling skin syndrome resembling epidermolysis bullosa simplex in a 10-month-old boy. Case Rep Dermatol 2013; 5:210.</a></li><li><a class="nounderline abstract_t">Hashimoto K, Hamzavi I, Tanaka K, Shwayder T. Acral peeling skin syndrome. J Am Acad Dermatol 2000; 43:1112.</a></li><li><a class="nounderline abstract_t">Kiritsi D, Cosgarea I, Franzke CW, et al. Acral peeling skin syndrome with TGM5 gene mutations may resemble epidermolysis bullosa simplex in young individuals. J Invest Dermatol 2010; 130:1741.</a></li><li><a class="nounderline abstract_t">Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol 2020; 183:614.</a></li><li><a class="nounderline abstract_t">Has C, Bruckner-Tuderman L. The genetics of skin fragility. Annu Rev Genomics Hum Genet 2014; 15:245.</a></li><li><a class="nounderline abstract_t">Lane EB, McLean WH. Keratins and skin disorders. J Pathol 2004; 204:355.</a></li><li><a class="nounderline abstract_t">Ngcungcu T, Oti M, Sitek JC, et al. Duplicated Enhancer Region Increases Expression of CTSB and Segregates with Keratolytic Winter Erythema in South African and Norwegian Families. Am J Hum Genet 2017; 100:737.</a></li><li><a class="nounderline abstract_t">Starfield M, Hennies HC, Jung M, et al. Localization of the gene causing keratolytic winter erythema to chromosome 8p22-p23, and evidence for a founder effect in South African Afrikaans-speakers. Am J Hum Genet 1997; 61:370.</a></li><li><a class="nounderline abstract_t">Mohamad J, Samuelov L, Malki L, et al. Palmoplantar keratoderma caused by a missense variant in CTSB encoding cathepsin B. Clin Exp Dermatol 2021; 46:103.</a></li><li><a class="nounderline abstract_t">Chang YY, van der Velden J, van der Wier G, et al. Keratolysis exfoliativa (dyshidrosis lamellosa sicca): a distinct peeling entity. Br J Dermatol 2012; 167:1076.</a></li><li><a class="nounderline abstract_t">Fiete D, Mi Y, Beranek M, et al. The glycan-specific sulfotransferase (R77W)GalNAc-4-ST1 putatively responsible for peeling skin syndrome has normal properties consistent with a simple sequence polymorphisim. Glycobiology 2017; 27:450.</a></li><li><a class="nounderline abstract_t">Pigors M, Sarig O, Heinz L, et al. Loss-of-Function Mutations in SERPINB8 Linked to Exfoliative Ichthyosis with Impaired Mechanical Stability of Intercellular Adhesions. Am J Hum Genet 2016; 99:430.</a></li><li><a class="nounderline abstract_t">Alfares A, Al-Khenaizan S, Al Mutairi F. Peeling skin syndrome associated with novel variant in FLG2 gene. Am J Med Genet A 2017; 173:3201.</a></li><li><a class="nounderline abstract_t">Bolling MC, Jan SZ, Pasmooij AMG, et al. Generalized Ichthyotic Peeling Skin Syndrome due to FLG2 Mutations. J Invest Dermatol 2018; 138:1881.</a></li><li><a class="nounderline abstract_t">Mohamad J, Sarig O, Godsel LM, et al. Filaggrin 2 Deficiency Results in Abnormal Cell-Cell Adhesion in the Cornified Cell Layers and Causes Peeling Skin Syndrome Type A. J Invest Dermatol 2018; 138:1736.</a></li><li><a class="nounderline abstract_t">Baenziger JU. Glycoprotein hormone GalNAc-4-sulphotransferase. Biochem Soc Trans 2003; 31:326.</a></li><li><a class="nounderline abstract_t">Garg K, Singh D, Mishra D. Peeling skin syndrome: Current status. Dermatol Online J 2010; 16:10.</a></li><li><a class="nounderline abstract_t">Ishida-Yamamoto A, Igawa S, Kishibe M. Order and disorder in corneocyte adhesion. J Dermatol 2011; 38:645.</a></li><li><a class="nounderline abstract_t">Mevorah B, Frenk E, Saurat JH, Siegenthaler G. Peeling skin syndrome: a clinical, ultrastructural and biochemical study. Br J Dermatol 1987; 116:117.</a></li><li><a class="nounderline abstract_t">Silverman AK, Ellis CN, Beals TF, Woo TY. Continual skin peeling syndrome. An electron microscopic study. Arch Dermatol 1986; 122:71.</a></li><li><a class="nounderline abstract_t">Sarma N, Boler AK, Bhanja DC. Peeling skin syndrome in eight cases of four different families from India and Bangladesh. Indian J Dermatol Venereol Leprol 2012; 78:625.</a></li><li><a class="nounderline abstract_t">Aras N, Sutman K, Tastan HB, et al. Peeling skin syndrome. J Am Acad Dermatol 1994; 30:135.</a></li><li><a class="nounderline abstract_t">Inamadar AC, Palit A. Peeling skin syndrome with aminoaciduria. Pediatr Dermatol 2005; 22:314.</a></li><li><a class="nounderline abstract_t">Cervantes T, Pham C, Browning JC. Superficial epidermolytic ichthyosis: a report of two families. Pediatr Dermatol 2013; 30:469.</a></li><li><a class="nounderline abstract_t">Lin Z, Zhao J, Nitoiu D, et al. Loss-of-function mutations in CAST cause peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads. Am J Hum Genet 2015; 96:440.</a></li><li><a class="nounderline abstract_t">Alkhalifah A, Chiaverini C, Del Giudice P, et al. PLACK syndrome resulting from a new homozygous insertion mutation in CAST. J Dermatol Sci 2017; 88:256.</a></li><li><a class="nounderline abstract_t">Mohamad J, Samuelov L, Ben-Amitai D, et al. PLACK syndrome shows remarkable phenotypic homogeneity. Clin Exp Dermatol 2019; 44:580.</a></li><li><a class="nounderline abstract_t">O'Sullivan S, Ozoemena L, Liu L, et al. PLACK syndrome: the penny dropped. Clin Exp Dermatol 2020; 45:1091.</a></li><li><a class="nounderline abstract_t">Boggs JME, Irvine AD. PLACK syndrome resulting from a novel homozygous variant in CAST. Pediatr Dermatol 2021; 38:210.</a></li><li><a class="nounderline abstract_t">Temel ŞG, Karakaş B, Şeker Ü, et al. A novel homozygous nonsense mutation in CAST associated with PLACK syndrome. Cell Tissue Res 2019; 378:267.</a></li><li><a class="nounderline abstract_t">Sawan ZA, Almehaidib A, Binamer Y, et al. PLACK syndrome is potentially treatable with intralipids. Clin Genet 2021; 99:572.</a></li><li><a class="nounderline abstract_t">Tolat SN, Gharpuray MB. Skin peeling syndrome. Cutis 1994; 53:255.</a></li><li><a class="nounderline abstract_t">Köse O, Safali M, Koç E, et al. Peeling skin diseases: 21 cases from Turkey and a review of the literature. J Eur Acad Dermatol Venereol 2012; 26:844.</a></li><li><a class="nounderline abstract_t">Kharfi M, Khaled A, Ammar D, et al. Generalized peeling skin syndrome: Case report and review of the literature. Dermatol Online J 2010; 16:1.</a></li><li><a class="nounderline abstract_t">Mizuno Y, Suga Y, Hasegawa T, et al. A case of peeling skin syndrome successfully treated with topical calcipotriol. J Dermatol 2006; 33:430.</a></li><li><a class="nounderline abstract_t">Israeli S, Zamir H, Sarig O, et al. Inflammatory peeling skin syndrome caused by a mutation in CDSN encoding corneodesmosin. J Invest Dermatol 2011; 131:779.</a></li><li><a class="nounderline abstract_t">Mallet A, Kypriotou M, George K, et al. Identification of the first nonsense CDSN mutation with expression of a truncated protein causing peeling skin syndrome type B. Br J Dermatol 2013; 169:1322.</a></li><li><a class="nounderline abstract_t">Telem DF, Israeli S, Sarig O, Sprecher E. Inflammatory peeling skin syndrome caused a novel mutation in CDSN. Arch Dermatol Res 2012; 304:251.</a></li><li><a class="nounderline abstract_t">Navarro-Navarro I, Jiménez-Gallo D, de la Varga-Martínez R, et al. Novel splice mutation in CDSN gene causing type b peeling skin syndrome. J Eur Acad Dermatol Venereol 2022; 36:e456.</a></li><li><a class="nounderline abstract_t">Ishida-Yamamoto A, Furio L, Igawa S, et al. Inflammatory peeling skin syndrome caused by homozygous genomic deletion in the PSORS1 region encompassing the CDSN gene. Exp Dermatol 2014; 23:60.</a></li><li><a class="nounderline abstract_t">Teye K, Hamada T, Krol RP, et al. Homozygous deletion of six genes including corneodesmosin on chromosome 6p21.3 is associated with generalized peeling skin disease. J Dermatol Sci 2014; 75:36.</a></li><li><a class="nounderline abstract_t">Teye K, Suga Y, Numata S, et al. A founder deletion of corneodesmosin gene is prevalent in Japanese patients with peeling skin disease: Identification of 2 new cases. J Dermatol Sci 2016; 82:134.</a></li><li><a class="nounderline abstract_t">Caubet C, Jonca N, Lopez F, et al. Homo-oligomerization of human corneodesmosin is mediated by its N-terminal glycine loop domain. J Invest Dermatol 2004; 122:747.</a></li><li><a class="nounderline abstract_t">Simon M, Jonca N, Guerrin M, et al. Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem 2001; 276:20292.</a></li><li><a class="nounderline abstract_t">Samuelov L, Sprecher E. Peeling off the genetics of atopic dermatitis-like congenital disorders. J Allergy Clin Immunol 2014; 134:808.</a></li><li><a class="nounderline abstract_t">Gordon H, Yap P, Hsiao KC, et al. A novel pathogenic variant in the corneodesmosin gene causing generalized inflammatory peeling skin syndrome with marked eosinophilia and trichorrhexis invaginata. Pediatr Dermatol 2022; 39:268.</a></li><li><a class="nounderline abstract_t">Bitoun E, Micheloni A, Lamant L, et al. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet 2003; 12:2417.</a></li><li><a class="nounderline abstract_t">Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25:141.</a></li><li><a class="nounderline abstract_t">Mägert HJ, Ständker L, Kreutzmann P, et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 1999; 274:21499.</a></li><li><a class="nounderline abstract_t">Mizuno Y, Suga Y, Muramatsu S, et al. A Japanese infant with localized ichthyosis linearis circumflexa on the palms and soles harbouring a compound heterozygous mutation in the SPINK5 gene. Br J Dermatol 2005; 153:661.</a></li><li><a class="nounderline abstract_t">Hausser I, Anton-Lamprecht I. Severe congenital generalized exfoliative erythroderma in newborns and infants: a possible sign of Netherton syndrome. Pediatr Dermatol 1996; 13:183.</a></li><li><a class="nounderline abstract_t">Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res 2013; 351:289.</a></li><li><a class="nounderline abstract_t">Mizuno Y, Suga Y, Haruna K, et al. A case of a Japanese neonate with congenital ichthyosiform erythroderma diagnosed as Netherton syndrome. Clin Exp Dermatol 2006; 31:677.</a></li><li><a class="nounderline abstract_t">El Shabrawi-Caelen L, Smolle J, Metze D, et al. Generalized exfoliative erythroderma since birth. Netherton syndrome. Arch Dermatol 2004; 140:1275.</a></li><li><a class="nounderline abstract_t">Prodinger C, Yerlett N, MacDonald C, et al. Characteristics of children with Netherton syndrome: a review of 21 patients. J Eur Acad Dermatol Venereol 2021; 35:e466.</a></li><li><a class="nounderline abstract_t">Bellon N, Hadj-Rabia S, Moulin F, et al. The challenging management of a series of 43 infants with Netherton syndrome: unexpected complications and novel mutations. Br J Dermatol 2021; 184:532.</a></li><li><a class="nounderline abstract_t">Chiticariu E, Hohl D. Netherton Syndrome: Insights into Pathogenesis and Clinical Implications. J Invest Dermatol 2020; 140:1129.</a></li><li><a class="nounderline abstract_t">Sun JD, Linden KG. Netherton syndrome: a case report and review of the literature. Int J Dermatol 2006; 45:693.</a></li><li><a class="nounderline abstract_t">Haliasos EC, Kerner M, Jaimes-Lopez N, et al. Dermoscopy for the pediatric dermatologist part I: dermoscopy of pediatric infectious and inflammatory skin lesions and hair disorders. Pediatr Dermatol 2013; 30:163.</a></li><li><a class="nounderline abstract_t">Burk C, Hu S, Lee C, Connelly EA. Netherton syndrome and trichorrhexis invaginata--a novel diagnostic approach. Pediatr Dermatol 2008; 25:287.</a></li><li><a class="nounderline abstract_t">Rakowska A, Kowalska-Oledzka E, Slowinska M, et al. Hair shaft videodermoscopy in netherton syndrome. Pediatr Dermatol 2009; 26:320.</a></li><li><a class="nounderline abstract_t">Macknet CA, Morkos A, Job L, et al. An infant with Netherton syndrome and persistent pulmonary hypertension requiring extracorporeal membrane oxygenation. Pediatr Dermatol 2008; 25:368.</a></li><li><a class="nounderline abstract_t">Pohl M, Zimmerhackl LB, Hausser I, et al. Acute bilateral renal vein thrombosis complicating Netherton syndrome. Eur J Pediatr 1998; 157:157.</a></li><li><a class="nounderline abstract_t">Utsumi D, Yasuda M, Amano H, et al. Hair abnormality in Netherton syndrome observed under polarized light microscopy. J Am Acad Dermatol 2020; 83:847.</a></li><li><a class="nounderline abstract_t">Samuelov L, Sarig O, Harmon RM, et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet 2013; 45:1244.</a></li><li><a class="nounderline abstract_t">Schlipf NA, Vahlquist A, Teigen N, et al. Whole-exome sequencing identifies novel autosomal recessive DSG1 mutations associated with mild SAM syndrome. Br J Dermatol 2016; 174:444.</a></li><li><a class="nounderline abstract_t">Cheng R, Yan M, Ni C, et al. Report of Chinese family with severe dermatitis, multiple allergies and metabolic wasting syndrome caused by novel homozygous desmoglein-1 gene mutation. J Dermatol 2016; 43:1201.</a></li><li><a class="nounderline abstract_t">Dănescu S, Leppert J, Cosgarea R, et al. Compound heterozygosity for dominant and recessive DSG1 mutations in a patient with atypical SAM syndrome (severe dermatitis, multiple allergies, metabolic wasting). J Eur Acad Dermatol Venereol 2017; 31:e144.</a></li><li><a class="nounderline abstract_t">Pan C, Cheng R, Li Y, et al. Deep-intronic and frameshift DSG1 variants associated with atypical severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome in a Chinese family. Eur J Dermatol 2021; 31:239.</a></li><li><a class="nounderline abstract_t">Srinivas SM, Basavanaik P, Gowdra A. A novel homozygous frameshift mutation in DSG1 gene in an Indian consanguineous family with severe dermatitis, multiple allergies and metabolic wasting syndrome. Indian J Dermatol Venereol Leprol 2021; 87:410.</a></li><li><a class="nounderline abstract_t">McAleer MA, Pohler E, Smith FJ, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol 2015; 136:1268.</a></li><li><a class="nounderline abstract_t">Paller AS, Czarnowicki T, Renert-Yuval Y, et al. The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. J Am Acad Dermatol 2018; 78:498.</a></li><li><a class="nounderline abstract_t">Liang J, Li C, Zhang Z, et al. Severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome caused by de novo mutation in the DSP gene misdiagnosed as generalized pustular psoriasis and treatment of acitretin with gabapentin. J Dermatol 2019; 46:622.</a></li><li><a class="nounderline abstract_t">Samuelov L, Sprecher E. Inherited desmosomal disorders. Cell Tissue Res 2015; 360:457.</a></li><li><a class="nounderline abstract_t">Has C, Jakob T, He Y, et al. Loss of desmoglein 1 associated with palmoplantar keratoderma, dermatitis and multiple allergies. Br J Dermatol 2015; 172:257.</a></li><li><a class="nounderline abstract_t">Ishida-Yamamoto A, Igawa S. Genetic skin diseases related to desmosomes and corneodesmosomes. J Dermatol Sci 2014; 74:99.</a></li><li><a class="nounderline abstract_t">Alexis B, Nathalie J, Audrey MB, et al. Peeling Skin Syndrome Type 1: Dupilumab Reduces IgE, But Not Skin Anomalies. J Clin Immunol 2022; 42:873.</a></li><li><a class="nounderline abstract_t">Gschwandtner M, Mildner M, Mlitz V, et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 2013; 68:37.</a></li><li><a class="nounderline abstract_t">Komatsu N, Suga Y, Saijoh K, et al. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. J Invest Dermatol 2006; 126:2338.</a></li><li><a class="nounderline abstract_t">Tan X, Bertonati C, Qin L, et al. Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins. Eur J Med Chem 2013; 70:661.</a></li><li><a class="nounderline abstract_t">Tan X, Furio L, Reboud-Ravaux M, et al. 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett 2013; 23:4547.</a></li><li><a class="nounderline abstract_t">Fischer J, Wu Z, Kantyka T, et al. Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury. J Invest Dermatol 2014; 134:1305.</a></li><li><a class="nounderline abstract_t">Teixeira TS, Freitas RF, Abrahão O Jr, et al. Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7. Bioorg Med Chem Lett 2011; 21:6112.</a></li><li><a class="nounderline abstract_t">Vasileiou Z, Barlos KK, Gatos D, et al. Synthesis of the proteinase inhibitor LEKTI domain 6 by the fragment condensation method and regioselective disulfide bond formation. Biopolymers 2010; 94:339.</a></li><li><a class="nounderline abstract_t">Valentin F, Wiegmann H, Tarinski T, et al. Development of a pathogenesis-based therapy for peeling skin syndrome type 1. Br J Dermatol 2021; 184:1123.</a></li></ol></div><div id="topicVersionRevision">Topic 15512 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7142468" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The peeling skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3977379" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Skin peeling syndrome in a Kurdish family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30032785" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Peeling Skin Disorders: A Paradigm for Skin Desquamation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380904" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19440220" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A missense mutation in TGM5 causes acral peeling skin syndrome in a Tunisian family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24628291" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Under-recognition of acral peeling skin syndrome: 59 new cases with 15 novel mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9126018" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acral peeling skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22289416" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Whole-exome sequencing in a single proband reveals a mutation in the CHST8 gene in autosomal recessive peeling skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20691404" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644735" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Novel TGM5 mutations in acral peeling skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23534700" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acral peeling skin syndrome resulting from a homozygous nonsense mutation in the CSTA gene encoding cystatin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26684698" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acral peeling skin syndrome associated with a novel CSTA gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22429841" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acral peeling skin syndrome in two East-African siblings: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25549719" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Adult-onset acral peeling skin syndrome in a non-identical twin: a case report in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22622422" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : TGM5 mutations impact epidermal differentiation in acral peeling skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25510201" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acral peeling skin syndrome resulting from mutations in TGM5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12210515" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epithelial barrier function: assembly and structural features of the cornified cell envelope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15803139" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The cornified envelope: a model of cell death in the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30593123" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transglutaminase diseases: from biochemistry to the bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15931780" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Acral peeling skin syndrome: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11390390" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32618001" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Phenotypic suppression of acral peeling skin syndrome in a patient with autosomal recessive congenital ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34713485" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Acral peeling skin syndrome resulting from a novel homozygous mutation in the CSTA gene-A report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22066523" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acral peeling skin syndrome: a clinically and genetically heterogeneous disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21944047" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mutations in CSTA, encoding Cystatin A, underlie exfoliative ichthyosis and reveal a role for this protease inhibitor in cell-cell adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25400170" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Epidermal barrier abnormalities in exfoliative ichthyosis with a novel homozygous loss-of-function mutation in CSTA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34379845" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acral peeling in Nagashima type palmo-plantar keratosis patients reveals the role of serine protease inhibitor B 7 in keratinocyte adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32247861" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Loss-of-Function Variants in SERPINA12 Underlie Autosomal Recessive Palmoplantar Keratoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24019772" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acral peeling skin syndrome resembling epidermolysis bullosa simplex in a 10-month-old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11100033" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acral peeling skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20164844" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acral peeling skin syndrome with TGM5 gene mutations may resemble epidermolysis bullosa simplex in young individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32017015" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24898041" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The genetics of skin fragility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15495218" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Keratins and skin disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28457472" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Duplicated Enhancer Region Increases Expression of CTSB and Segregates with Keratolytic Winter Erythema in South African and Norwegian Families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9311742" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Localization of the gene causing keratolytic winter erythema to chromosome 8p22-p23, and evidence for a founder effect in South African Afrikaans-speakers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32683719" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Palmoplantar keratoderma caused by a missense variant in CTSB encoding cathepsin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23039091" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Keratolysis exfoliativa (dyshidrosis lamellosa sicca): a distinct peeling entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28204496" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The glycan-specific sulfotransferase (R77W)GalNAc-4-ST1 putatively responsible for peeling skin syndrome has normal properties consistent with a simple sequence polymorphisim.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27476651" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Loss-of-Function Mutations in SERPINB8 Linked to Exfoliative Ichthyosis with Impaired Mechanical Stability of Intercellular Adhesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28884927" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Peeling skin syndrome associated with novel variant in FLG2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29505760" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Generalized Ichthyotic Peeling Skin Syndrome due to FLG2 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29758285" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Filaggrin 2 Deficiency Results in Abnormal Cell-Cell Adhesion in the Cornified Cell Layers and Causes Peeling Skin Syndrome Type A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12653629" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Glycoprotein hormone GalNAc-4-sulphotransferase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20233567" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Peeling skin syndrome: Current status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21545505" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Order and disorder in corneocyte adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2434123" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Peeling skin syndrome: a clinical, ultrastructural and biochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2935089" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Continual skin peeling syndrome. An electron microscopic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22960820" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Peeling skin syndrome in eight cases of four different families from India and Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8277017" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Peeling skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16060866" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Peeling skin syndrome with aminoaciduria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22612346" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Superficial epidermolytic ichthyosis: a report of two families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25683118" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Loss-of-function mutations in CAST cause peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28851602" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : PLACK syndrome resulting from a new homozygous insertion mutation in CAST.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30656735" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : PLACK syndrome shows remarkable phenotypic homogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32918489" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : PLACK syndrome: the penny dropped.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33010050" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : PLACK syndrome resulting from a novel homozygous variant in CAST.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31392520" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A novel homozygous nonsense mutation in CAST associated with PLACK syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33410500" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : PLACK syndrome is potentially treatable with intralipids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8039417" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Skin peeling syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21711468" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Peeling skin diseases: 21 cases from Turkey and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20233558" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Generalized peeling skin syndrome: Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16700837" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A case of peeling skin syndrome successfully treated with topical calcipotriol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21191406" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Inflammatory peeling skin syndrome caused by a mutation in CDSN encoding corneodesmosin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23957618" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Identification of the first nonsense CDSN mutation with expression of a truncated protein causing peeling skin syndrome type B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22146835" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Inflammatory peeling skin syndrome caused a novel mutation in CDSN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35067988" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Novel splice mutation in CDSN gene causing type b peeling skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24372652" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Inflammatory peeling skin syndrome caused by homozygous genomic deletion in the PSORS1 region encompassing the CDSN gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24794518" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Homozygous deletion of six genes including corneodesmosin on chromosome 6p21.3 is associated with generalized peeling skin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26867961" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A founder deletion of corneodesmosin gene is prevalent in Japanese patients with peeling skin disease: Identification of 2 new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086562" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Homo-oligomerization of human corneodesmosin is mediated by its N-terminal glycine loop domain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279026" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25282561" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Peeling off the genetics of atopic dermatitis-like congenital disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35178752" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A novel pathogenic variant in the corneodesmosin gene causing generalized inflammatory peeling skin syndrome with marked eosinophilia and trichorrhexis invaginata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915442" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10835624" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10419450" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : LEKTI, a novel 15-domain type of human serine proteinase inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120162" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A Japanese infant with localized ichthyosis linearis circumflexa on the palms and soles harbouring a compound heterozygous mutation in the SPINK5 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8806118" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Severe congenital generalized exfoliative erythroderma in newborns and infants: a possible sign of Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23344365" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901309" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A case of a Japanese neonate with congenital ichthyosiform erythroderma diagnosed as Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492197" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Generalized exfoliative erythroderma since birth. Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33725371" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Characteristics of children with Netherton syndrome: a review of 21 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32479644" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The challenging management of a series of 43 infants with Netherton syndrome: unexpected complications and novel mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32446331" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Netherton Syndrome: Insights into Pathogenesis and Clinical Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16796630" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Netherton syndrome: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23405886" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Dermoscopy for the pediatric dermatologist part I: dermoscopy of pediatric infectious and inflammatory skin lesions and hair disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18429812" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Netherton syndrome and trichorrhexis invaginata--a novel diagnostic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706096" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Hair shaft videodermoscopy in netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18577046" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : An infant with Netherton syndrome and persistent pulmonary hypertension requiring extracorporeal membrane oxygenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9504792" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Acute bilateral renal vein thrombosis complicating Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32029302" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Hair abnormality in Netherton syndrome observed under polarized light microscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23974871" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26288349" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Whole-exome sequencing identifies novel autosomal recessive DSG1 mutations associated with mild SAM syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27154412" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Report of Chinese family with severe dermatitis, multiple allergies and metabolic wasting syndrome caused by novel homozygous desmoglein-1 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27632246" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Compound heterozygosity for dominant and recessive DSG1 mutations in a patient with atypical SAM syndrome (severe dermatitis, multiple allergies, metabolic wasting).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33818390" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Deep-intronic and frameshift DSG1 variants associated with atypical severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome in a Chinese family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33666035" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A novel homozygous frameshift mutation in DSG1 gene in an Indian consanguineous family with severe dermatitis, multiple allergies and metabolic wasting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26073755" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29066275" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31106887" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome caused by de novo mutation in the DSP gene misdiagnosed as generalized pustular psoriasis and treatment of acitretin with gabapentin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25487406" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Inherited desmosomal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25041099" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Loss of desmoglein 1 associated with palmoplantar keratoderma, dermatitis and multiple allergies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24636350" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Genetic skin diseases related to desmosomes and corneodesmosomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35194710" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Peeling Skin Syndrome Type 1: Dupilumab Reduces IgE, But Not Skin Anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157658" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16778802" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24211642" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23849879" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24352040" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903387" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20069636" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Synthesis of the proteinase inhibitor LEKTI domain 6 by the fragment condensation method and regioselective disulfide bond formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926582" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Development of a pathogenesis-based therapy for peeling skin syndrome type 1.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
